[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"calcitonin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:calcitonin":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100641127","phase-3-subcutaneous-calcitonin-in-acute-herpes-zoster-100641127",false,"NCT07655804","Subcutaneous Calcitonin in Acute Herpes Zoster","The Prophylactic Value of Subcutaneous Calcitonin in Acute Herpes Zoster Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* patients aged ≥ 50 years, with acute herpes zoster infection (rash duration \\\u003C 7 days) and moderate to severe pain.\n\nExclusion Criteria:\n\n* Coagulation abnormalities\n* Pre-existing other pain syndrome or psychological disorders.\n* Severe hepatic, cardiovascular, or renal disorders.\n* Allergy to calcitonin.","ALL","50 Years",{"count":19,"type":20},168,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.",[26,27,28],"Calcitonin","Subcutaneous","Acute Herpes Zoster","NOT_YET_RECRUITING","2026-06-13",{"date":32,"type":33},"2026-06-18","ACTUAL",{"date":35,"type":20},"2026-07-01",{"date":37,"type":20},"2027-10-01",{"name":39,"class":40},"Tanta University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":41},"100501163","calcitonin-therapy-on-incidence-and-severity-of-neuropathic-pain-after-spinal-cord-injury-100501163","NCT05805683","Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury","Effect of Early Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury","Inclusion Criteria:\n\n* Patients aged ≥18 years, with spinal cord injury at any level and any degree of completeness in the early stage of trauma.\n\nExclusion Criteria:\n\n* Intake of anticonvulsants medications.\n* Evidence of neuropathic pain.\n* Evidence of previous allergic reaction to calcitonin.\n* Patients with renal, hepatic and cardiac dysfunction or neurological disorders .\n* brain damage or major trauma to extremities or abdomen.",true,"18 Years",{"count":52,"type":20},126,[54],"NA","This prospective randomized double blinded study will be conducted to evaluate the effect of early pharmacologic intervention with calcitonin on the incidence or the severity of neuropathic pain after spinal cord injury",[26,57,58],"Neuropathic Pain","Spinal Cord Injury",[26,60,61],"Neuropathic pain","Spinal cord injury","RECRUITING","2026-05-11",{"date":65,"type":33},"2026-05-14",{"date":67,"type":33},"2023-05-01",{"date":69,"type":20},"2028-05-01",{"name":39,"class":40}]